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Pervanadate activation of intracellular kinases leads to tyrosine
phosphorylation and shedding of syndecan-1
Jane REILAND*§, Vanessa L. OTT*†, Connie S. LEBAKKEN*†, Charles YEAMAN*†, James MCCARTHY‡
and Alan C. RAPRAEGER*†s
*Department of Pathology and Laboratory Medicine, and †Graduate Program in Cellular and Molecular Biology, University of Wisconsin, Madison, WI 53706, U.S.A. and
‡Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, U.S.A.
Syndecan-1 is a transmembrane haparan sulphate proteoglycan
that binds extracellular matrices and growth factors, making it a
candidate to act between these regulatory molecules and in-
tracellular signalling pathways. It has a highly conserved trans-
membrane}cytoplasmic domain that contains four conserved
tyrosines. One of these is in a consensus sequence for tyrosine
kinase phosphorylation. As an initial step to investigating
whether or not phosphorylation of these tyrosines is part of a
signal-transduction pathway, we have monitored the tyrosine
phosphorylation of syndecan-1 by cytoplasmic tyrosine kinases
in intact cells. Tyrosine phosphorylation of syndecan-1 is ob-
served when NMuMG cells are treated with sodium ortho-
vanadate or pervanadate, which have been shown to activate
intracellular tyrosine kinases. Initial studies with sodium ortho-
vanadate demonstrate a slow accumulation of phosphotyrosine
on syndecan-1 over the course of several hours. Pervanadate,
a more effective inhibitor of phosphatases, allows detection of
INTRODUCTION
Regulation of cellular function by a combination of growth
factors and extracellular matrix proteins is a subject of growing
interest. Syndecan-1 is a heparan sulphate proteoglycan that
binds growth factors and extracellular matrix components via its
heparan sulphate chains and is thus a candidate for helping to
convey signals from the extracellular matrix to the cytoplasm
[1,2]. Syndecan-1 binds extracellular matrix proteins such as
fibronectin, thrombospondin, collagen types I, III, V and tenascin
[3–6]. It also binds ‘heparin-binding’ growth factors such as
members of the fibroblast growth factor family, first shown
by Kiefer et al. [7]. The binding of fibroblast growth factor by
heparan sulphate proteoglycans is an important step in the
growth factor’s biological action [8–10]. In addition to binding
its extracellular ligands, it is proposed that syndecan-1 attaches
to the actin cytoskeleton through its cytoplasmic domain [11,12].
Syndecan-1 is a member of the syndecan family that consists
of four proteoglycans expressed in vertebrate cells (syndecans
1–4; see [1]). The defining characteristic of the syndecan family
is a highly conserved transmembrane and cytoplasmic domain
which contains four conserved tyrosines and a variable number
of serines}threonines that may serve as phosphorylation sites.
Phosphorylation is an important means of propagating in-
tracellular signals. Many growth factor receptors have tyrosine
kinase domains that are activated in response to binding their
respective ligands (for recent reviews see [13,14]). Activation
Abbreviations used: DMEM, Dulbecco’s modified Eagle’s medium; NEM, N-ethylmaleimide; PLC-γ, phospholipase C-γ ; mAb, monoclonal antibody;
PMA, phorbol 12-myristate 13-acetate ; PKC, protein kinase C.
§ Present address : Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, U.S.A.
s To whom correspondence should be addressed.
phosphotyrosine on syndecan-1 within 5 min, with peak phos-
phorylation seen by 15 min. Concurrently, in a second process
activated by pervanadate, syndecan-1 ectodomain is cleaved and
released into the culture medium. Two phosphorylated fragments
of syndecan-1 of apparent sizes 6 and 8 kDa remain with the cell
after shedding of the ectodomain. The 8 kDa size class appears
to be a highly phosphorylated form of the 6 kDa product, as it
disappears if samples are dephosphorylated. These fragments
contain the C-terminus of syndecan-1 and also retain at least a
portion of the transmembrane domain, suggesting that they are
produced by a cell surface cleavage event. Thus pervanadate
treatment of cells results in two effects of syndecan-1: (i)
phosphorylation of one or more of its tyrosines via the action of
a cytoplasmic kinase(s) and (ii) cleavage and release of the
ectodomain into the medium, producing a C-terminal fragment
containing the transmembrane}cytoplasmic domain.
leads to phosphorylation of the receptors themselves and in-
itiation of a cascade of phosphorylation events that activate or
deactivate a wide variety of other kinases and regulatory mole-
cules, ultimately resulting in changes in cellular behaviour [15].
Other growth factor receptors lack inherent kinase activity, but
associate with intracellular kinases when bound to an extra-
cellular ligand [13,14]. In a similar fashion, the extracellular
matrix can also generate such intracellular signals by binding and
triggering receptors (e.g. integrins) that are not kinases them-
selves, but localize and activate kinases such as focal adhesion
kinase (pp125FAK ) and Src in response to ligand binding [16–19].
The report of syndecan-4 localization in focal adhesions suggests
the potential involvement of syndecans in adhesion-induced
signalling [20]. Recent reports demonstrate a direct mechanism
for the activation of ras by integrin-mediated signals [21]. In
many cases, such signals are initiated by the phosphorylation of
proteins on tyrosines, which interact with regulatory molecules
containing SH2 phosphotyrosine-binding domains (reviewed in
[22,23]). These molecules in turn often contain enzymic activities
capable of further propagating a signal.
Although syndecan-1 itself does not have a kinase domain that
could initiate a phosphorylation cascade, the four conserved
tyrosines of its cytoplasmic domain have the potential to trans-
duce a signal if phosphorylated (see Figure 1A). One of the
tyrosines is contained in the sequence motif KKDEGSY, which
is exactly conserved in all vertebrate syndecans and in the
Drosophila syndecan [24] and fits the consensus sequence for
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tyrosine kinase phosphorylation [25,26]. It has also been pro-
posed that phosphorylation of the cytoplasmic domain may serve
to regulate the association of the protein with the cytoskeleton
[25]. The role of the proteoglycan in dictating cell morphology
may also be regulated via cleavage of the extracellular domain of
the syndecan, thus divorcing the cell from its matrix anchorage.
A dibasic amino acid sequence present in syndecans-1–3 has been
proposed as a likely target for a cell surface protease that would
carry out this function [25–27]. The location of the cleavage site
is questioned, however, by the more recent cloning of the
Drosophila syndecan, which is shed by cultured cells despite
lacking the dibasic sequence altogether [24].
To investigate the potential phosphorylation of syndecan-1
by cellular tyrosine kinases, we have utilized pervanadate.
Pervanadate is a powerful phosphatase inhibitor that leads to
the accumulation of phosphorylated proteins and the activation
of kinases that are normally retained in inactive forms
by dephosphorylation [28,29]. Pervanadate activation of the
phosphorylation process in NMuMG epithelial cells and
syndecan-1-transfected Raji lymphoid cells results in the rapid
phosphorylation of tyrosine in the syndecan-1 cytoplasmic
domain. Secondly, the extracellular domain of syndecan-1 is shed
due to cleavage at the cell surface, presumably via activation
of a membrane protease via an intracellular signalling
mechanism.
MATERIALS AND METHODS
Cell culture and treatments
Normal murine mammary gland (NMuMG) cells were cultured
to 70% confluency in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated calf serum
(Hyclone Laboratories, Logan, UT, U.S.A.), 100 units}ml peni-
cillin, 100 µg}ml streptomycin and 10 µg}ml insulin [30].
Syndecan-expressing human Raji lymphoid cells [31] were cul-
tured in RPMI 1640 medium supplemented with 10% heat-
inactivated calf serum, and penicillin}streptomycin.
Generation of syndecan-1-specific antibody S1CD
A ten-amino acid peptide (KPTKQEEFYA) corresponding to
the C-terminus of syndecan-1 was synthesized by Multiple
Peptide Systems (San Diego, CA, U.S.A.). An additional cysteine
residue was added to the N-terminus of the peptide to facilitate
its coupling to keyhole limpet haemocyanin, used as a carrier
protein for the immunization of rabbits. Peptide-specific anti-







chromatography on peptide coupled to SulfoLink gel (Pierce,
Rockford, IL, U.S.A.). Bound antibodies were eluted with 0±1 M
glycine (pH 2±8) and immediately neutralized with 1 M Tris}HCl,
pH 9±5. Specificity of the antibodies was determined by immuno-
blotting lysates of NMuMG, Raji parental and Raji syndecan-1-
transfected cells ; the antibody recognizes the decorated proteo-
glycan, the core protein after removal of the glycosaminoglycan
chains, and a 12 kDa peptide consisting of the transmembrane
and cytoplasmic domains of the core protein, which is maintained
with the cell lysate after trypsin cleavage. Pre-adsorption of
antibody with the immunization peptide results in the loss of all
staining. This antibody is designated S1CD and has also been
used elsewhere [31].
Immunoprecipitation
Cells (1¬10(}ml) were lysed in extraction buffer (PBS containing
5% Triton X-100, 0±1% SDS, 1 mM PMSF, 1 mM N-ethyl-





) at 4 °C for 10 min. Insoluble cell debris was removed by
centrifugation at 5000 g for 5 min and then 3¬10( cell equivalents
of lysate were incubated with 7±5 µg}ml S1CD and 50 µl of
protein A-agarose for 2 h at 4 °C. Pellets were washed four times
with PBS containing 1 mM PMSF, 1 mM NEM, 0±1 mM sodium




, then extracted in sample buffer
(190 mM Tris, pH 8±45, containing 0±5% glycerol, 1% SDS,
1 mg}ml Bromophenol Blue, 1 mM PMSF, 1 mM NEM,











and then immunoprecipitated as above.
The pellets were washed 3 times with PBS containing 1 mM
PMSF and 1 mM NEM and then with 25 mM Mes, pH 6,
containing 1 mM PMSF and 1 mM NEM. Pellets were heated
on a boiling water bath for 5 min, cooled to 32 °C and potato
acid phosphatase (Calbiochem, San Diego, CA, U.S.A.) in 25
Mes, pH 6, was added to a final concentration of 30 units}ml.
Samples were incubated for 2 h at 37 °C, then extracted in
sample buffer.
Immunoblotting
Samples were heated to 95 °C for 5 min and electrophoresed in
a Tris}Tricine SDS}PAGE buffer system, [32] on a 5}16%
polyacrylamide step gel and electrophoretically transferred to
cationic membrane (Zeta-probe, Bio-Rad, Rockville Center,
NY, U.S.A.) for 14 h at 50 V in 12±5 mM Trizma base and
100 mM glycine. The membrane was fixed with 0±05% glutaral-
dehyde in PBS for 30 min at room temperature, rinsed, and
incubated first in blocking solution (PBS containing 5% non-fat
dry milk, 0±5% Nonidet P40 and 0±3% Tween 20) for 2 h at 37 °C
and then in PBS containing 50 µg}ml heparin (Sigma, St. Louis,
MO, U.S.A.) and 0±1% Nonidet P40 for 30 min at 37 °C. The
heparin aids in blocking the cationic sites and reducing back-
ground. Blots were then incubated with 1:1000 dilution of anti-
phosphotyrosine antibody (PY-20; ICN Biomedicals) for 2 h at
room temperature in PBS containing 1% BSA and 0±02%
NaN
$
, then washed five times with PBS containing 0±1% Nonidet
P40. Blots were further incubated with biotin-conjugated anti-
mouse immunoglobulin (Jackson ImmunoResearch Labora-
tories, West Grove, PA, U.S.A.) in PBS containing 0±1% Nonidet
P40 for 30 min, then washed and incubated with horseradish
peroxidase-conjugated anti-mouse immunoglobulin (Amersham
Corp., Arlington Heights, IL, U.S.A.) and horseradish per-
oxidase streptavidin (Amersham Corp.) in PBS containing 0±1%
Nonidet P40 for 45 min, then finally washed and detected with
an enhanced chemiluminescence kit (ECL; Amersham Corp.)
according to the manufacturer’s instructions.
The phosphotyrosine-detected blots were then washed and
incubated with 0±1 µg}ml S1CD in blocking solution with
25 µg}ml heparin for 2 h, washed 5 times with PBS containing
0±1% Nonidet P40 and then incubated with alkaline phos-
phatase-conjugated anti-rabbit antibody (Jackson Immuno-
Research Laboratories) in blocking solution containing 25 µg}ml
heparin. Blots were washed 5 times with PBS containing 0±1%
Nonidet P40 and then twice with alkaline phosphatase buffer
(100 mM Tris, pH 9±5, containing 100 mM NaCl and 5 mM
MgCl
#
) and detected with Lumi-Phos2 530 according to the
manufacturer’s instructions (Boehringer-Mannheim, Indiana-
polis, IN, U.S.A.).
Phospholipase C-γ (PLC-γ) was detected on blots with an
anti-PLC-γ monoclonal antibody (mAb) (Upstate Biotechnology
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Inc., Lake Placid, NY, U.S.A.) with processing similar to the
phosphotyrosine blots.
Phosphoamino acid analysis
NMuMG cells were incubated as described above with the





was used. Cells were prelabelled for 4 h with 0±75 mCi}ml $#PO
%
(DuPont–NEN, Boston, MA, U.S.A.) at 37 °C, then treated with
pervanadate for 15 min, washed and treated with trypsin to
generate the syndecan-1 C-terminal fragment. The fragment was
immunoprecipitated with S1CD, subjected to PAGE and trans-
ferred to Zeta-Probe membrane. Radiolabelled protein was
localized on the membrane by autoradiography, and the
syndecan-1 C-terminal band was excised and incubated in 6 M
HCl at 100 °C for 1±5 h. Samples were lyophilized and pellets
resuspended in 20 µl of double-distilled water containing
1 mg}ml each unlabelled phosphoserine, phosphothreonine and
phosphotyrosine (Sigma). A 2 µl aliquot of the sample was
applied to a 0±25 mm cellulose TLC plate, and separated by
electrophoresis at 1 kV for 1 h at 4 °C in pyridine}acetic acid}
water (1:10:189, by vol.) (pH 3±5). The radiolabelled phospho-
amino acids on the plate were identified by autoradiography and
the phosphoamino acid standards were identified by spraying
with 0±2% ninhydrin in ethanol (Sigma).
Triton X-114 phase separation of cellular proteins
NMuMG cells were solubilized in PBS containing 1% Triton X-
114, 1 mM PMSF and 1 mM NEM at 4 °C for 10 min and then
centrifuged at 5000 g for 10 min. An aliquot of the lysate was
reserved for immunoprecipitation without further treatment and
the remaining lysate was subjected to phase separation as
described by Tiruppathi et al. [33]. After phase separation,
Triton X-114 was added to a final concentration of 0±5% to the
aqueous phase and Tris-buffered saline (10 mM Tris}0±15 M
NaCl, pH 7±4) was added to restore the original volume of the
detergent phase; the samples were subsequently immuno-
precipitated.
Quantitative analysis of medium and cell-associated syndecan-1
Cells were washed 4 times with 20 mM Hepes-buffered DMEM
at 37 °C. Cells were incubated with this medium containing
0±1% BSA with or without pervanadate for 30 min at 37 °C.
Medium was removed and brought to 8 M urea. Cells were
washed 5 times with PBS at 4 °C and extracted (2±5¬10' cell
equivalents}ml) in TUT (10 mM Tris, pH 8, 8 M urea, 0±1%




) at 4 °C. Proteoglycans from
cells and medium were isolated by incubation with DEAE-
Sepharose (Pharmacia) for 1±5 h at 4 °C, and eluted in Microfuge
spin columns with 100 mM Hepes, pH 6±5, containing 1 M NaCl,
10 mM CaCl
#
, 20 mM sodium acetate and 0±2 mg}ml BSA. Sam-
ples were brought to 0±3 M NaCl and serial dilutions in TBS
were applied to Zeta-probe membrane equilibrated in TBS. The
Zeta-probe membrane was incubated for 30 min with 0±05%
glutaraldehyde, washed in PBS and incubated for 2 h in blocking
buffer containing 25 µg}ml heparin at 37 °C. Blots were then
incubated for 2 h with 1±0 µg}ml mAb 281±2 in blocking buffer,
washed 5 times with PBS and 0±1% Nonidet P40, and then
incubated with alkaline phosphatase-conjugated anti-rat anti-
body (Jackson ImmunoResearch Laboratories). The blots were
washed 5 times in PBS, then once more in alkaline phosphatase
buffer and detected using Lumi-Phos2 530 according to the
manufacturer’s directions.
RESULTS
Syndecan-1 is phosphorylated in vanadate-treated NMuMG cells
NMuMG cells express abundant levels of cell surface syndecan-
1 [12]. The expression of this protein can be visualized via
immunoblot analysis as intact proteoglycan, which migrates as
a diffuse band, or as an enzymically denuded core protein, which
migrates as a discrete band at 80 kDa. Alternatively, treatment
of cells with mild trypsin rapidly cleaves the syndecan-1 core
protein, leaving a cell-associated protein fragment consisting of
the C-terminal cytoplasmic and transmembrane domains (C-
terminal fragment). To isolate syndecan-1 C-terminal fragment,
trypsin-treated cells were lysed and subjected to immuno-
precipitation with an affinity-purified polyclonal antibody
(S1CD) to the ten C-terminal amino acids of syndecan-1 (Figure
1A). The immunoprecipitated C-terminal fragment migrates as a
12 kDa fragment by gel electrophoresis. However, this is likely
to be an inaccurate size assessment as the core protein, which
migrates at over twice its calculated mass of 33 kDa, is notorious
for anomalous migration.
The C-terminal fragment contains four tyrosines, with three
exposed in the cytoplasmic domain (Figure 1A). To assess
potential phosphorylation of these tyrosines, blots of S1CD
immunoprecipitateswereprobedwithmAbs specific for phospho-
tyrosine. However, this analysis failed to detect phosphorylated
syndecan-1 (Figure 1B). In an attempt to retain phosphoryl-
ated tyrosines that may be dephosphorylated by phosphatases,
NMuMG cells were pretreated with sodium orthovanadate,
a general inhibitor of tyrosylphosphatases [34]. Treatment of
cells for 1 h with orthovanadate results in significant syndecan-1
phosphorylation, as shown by the appearance of a tyrosine-
phosphorylated band at 12 kDa in trypsin-treated cells (Figure
1B). The phosphorylation reaches a maximum by 3 h and
is decreased by 6 h. Subsequent immunostaining of the blots
with S1CD identifies the 12 kDa band as the C-terminal
syndecan-1 fragment and demonstrates that this fragment is
present on the blots at similar levels at all time points (Figure
1B). A faint band of a smaller product is consistently seen in the
1 and 3 horthovanadate-treated samples and appears to represent
a cleavage product of syndecan-1 which will be discussed in
detail below.
Syndecan-1 is rapidly phosphorylated in pervanadate-treated
NMuMG cells
The accumulation of phosphorylated syndecan-1 in ortho-
vanadate-treated cells suggests either (i) that syndecan-1 is
constitutively phosphorylated at low levels and that ortho-
vanadate inhibits a phosphatase which rapidly dephosphorylates
the protein or (ii) that the inhibition of cellular phosphatases
leads to activation of a cytoplasmic kinase that recognizes and
phosphorylates syndecan-1. In either case, the accumulation of
phosphorylated protein is a slow process, suggesting that ortho-
vanadate may be a relatively inefficient inhibitor of phosphatases
under these conditions. To inhibit phosphatases more effectively
and lead to the activation of intracellular tyrosine kinases, we





to sodium orthovanadate (e.g. pervanadate) [28].
NMuMG cells pretreated with pervanadate (100 µM vanadate




) for up to 30 min are viable but exhibit a more
elongated shape (results not shown). Isolation of the syndecan-
1 C-terminal fragment from pervanadate-treated cells provides
several important results. First, cells treated with pervanadate
cleave the C-terminal fragment into several products (Figure
2A). In addition to the 12 kDa product produced by trypsin
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B
Figure 1 Phosphorylation of syndecan-1 cytoplasmic domain phosphorylation in orthovanadate
(A) The deduced amino acid sequence of the mouse syndecan-1 core protein [27] shows the four conserved tyrosines of the transmembrane/cytoplasmic domain in bold and a tyrosine kinase
consensus phosphorylation sequence [25,26] adjacent to tyrosine-287 in italics. The transmembrane domain is underlined with a solid line and the recognition site for antibody S1CD is shown
by a dashed line. (B) NMuMG cells were incubated with 1 mM sodium orthovanadate for 0, 1, 3 or 6 h at 37 °C, suspended by treatment with trypsin and then lysed in detergent. The C-terminal
fragment of syndedan-1 was immunoprecipitated with S1CD, resolved by gel electrophoresis, transferred to Zeta-probe membrane and immunostained with either PY-20 (upper panel) or S1CD
(lower panel).
Figure 2 Time course of syndecan-1 cytoplasmic domain phosphorylation
in pervanadate
NMuMG cells were treated with pervanadate (3 mM H2O2 and 0±1 M vanadate) for 0, 5, 15 or
30 min. S1CD immunoprecipitates from trypsin-treated cells were resolved by gel electrophoresis,
transferred to Zeta-probe membrane and immunostained with (A) S1CD or (B) PY-20.
(seen as a single band lacking tyrosine phosphorylation at zero
time), bands are resolved by SDS}PAGE at 6, 8 and 14 kDa,
although the 8 and 14 kDa products are not found consistently
in all experiments. These products are immunoreactive with
S1CD antibody, indicating that they all retain the C-terminus of
syndecan-1. At all time points, the syndecan-1 C-terminal frag-
ment is present in equivalent amounts.
The second finding is that within 5 min of pervanadate addition
at 37 °C, syndecan-1 is phosphorylated on tyrosine (Figure 2B),
based on immunoreactivity with anti-phosphotyrosine antibody.
Phosphorylation is detected primarily on the 6, 8 and 14 kDa
bands. Tyrosine phosphorylation reaches a maximum within
15 min and is still prevalent at 30 min. Without pervanadate
treatment at 37 °C, phosphorylation of syndecan-1 is not detected
(Figure 2B). Phosphorylation does not occur at 4 °C with
Figure 3 Phosphoamino acid analysis of syndecan-1 C-terminal fragment
S1CD immunoprecipitates of pervanadate-treated and trypsin-treated NMuMG cells labelled with
32PO4 were resolved by gel electrophoresis and transferred to cationic membrane. The
syndecan-1 C-terminal fragment on a membrane strip was hydrolysed and amino acids were
separated by electrophoresis on a TLC plate. Radiolabelled amino acids were detected by
autoradiography and compared with the positions of the phosphoamino acid standards as
indicated by the dashed circles.
pervanadate, as all samples are treated with trypsin on ice in the
presence of pervanadate for 10 min and only the cells previously
incubated at 37 °C phosphorylate syndecan-1.
The diversity of bands may reflect phosphorylation and
endogenous cleavage. The 14 kDa band probably represents the
phosphorylated form of the C-terminal fragment generated by
trypsin cleavage, which would otherwise be observed at 12 kDa.
During longer pervanadate treatments, the 12 and 14 kDa bands
disappear, apparently as the result of endogenous cleavage. In
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Figure 4 Both H2O2 and vanadate are required for syndecan-1 phosphoryl-
ation at short time points
NMuMG cells were treated with the indicated concentrations (mM) of vanadate and H2O2 for
15 min at 37 °C. S1CD immunoprecipitates from trypsin-treated cells were resolved by gel
electrophoresis, transferred to Zeta-probe membrane and immunostained with (A) PY-20 or (B)
S1CD.
concert with this endogenous cleavage, the 6 and 8 kDa bands
become the major products, with the 8 kDa product possibly
representing a hyperphosphorylated version of the 6 kDa protein.
The ability to resolve these as distinct bands was variable in some
experiments.
Phosphoamino acid analysis confirms that syndecan-1 is phos-
phorylated on tyrosine. Treatment of the cellswith $#PO
%
followed
by a 15 min treatment with pervanadate and subsequent isolation
of the syndecan-1 C-terminal fragment shows incorporation of
label into 6–8 and 12 kDa bands that coincide with S1CD
immunolocalization on blots (not shown). These labelled bands
are not seen in the absence of S1CD immunoprecipitation.
Excision of the combined 6–12 kDa bands and analysis of the
hydrolysed protein by TLC demonstrates that the label is almost
entirely in phosphotyrosine, although a small amount of phos-
phoserine is also detected (Figure 3).
Both H2O2 and vanadate are required for syndecan-1





alone can mimic some aspects of growth factor signalling














alone or with 0±1 mM vanadate together with




(Figure 4). There is no





, or when there is no pretreatment (Figure 4).
Syndecan-1 is tyrosine-phosphorylated when cells are treated










more effective. Immunostaining with S1CD demonstrates that
multiple phosphorylated syndecan-1 C-terminal fragments are
precipitated (Figure 4B). The primary products are the 12 kDa
product resulting from trypsin treatment and the 6–8 kDa





alone results in a small amount of the 6–8 kDa products,
although no phosphorylation is detected. Vanadate alone or no
treatment fails to produce cleavage products (Figure 4A).
Syndecan-1 transfected into Raji cells is phosphorylated
Themultiple phosphorylated bands found in pervanadate-treated
NMuMG cells all react with S1CD indicating that they contain
the C-terminus of syndecan-1. However, NMuMG cells express
other members of the syndecan family which contain highly
homologous cytoplasmic domains. To verify that the multiple
bands were all cleavage products of the syndecan-1 core protein,
Figure 5 Tyrosine phosphorylation of syndecan-1 in Raji syndecan-1
transfectants
Raji parental cells (lanes 1 and 3) or Raji cells transfected with syndecan-1 (lanes 2 and 4)
were pretreated with pervanadate for 15 min at 37 °C, treated with trypsin, and syndecan-1 C-
terminal fragments were immunoprecipitated with S1CD. Immunoprecipitates were resolved by
gel electrophoresis, transferred to Zeta-probe membrane and immunostained with S1CD (lanes
1 and 2) or PY-20 (lanes 3 and 4).
and not due to cross-reactivity with the other syndecans present
in NMuMG cells, we examined either native Raji cells, which are
syndecan-negative, or Raji S-1 cells that had been transfected
with the cDNA for syndecan-1 and express syndecan-1 at the cell
surface [31]. When Raji S-1 cells are treated with pervanadate
followed by trypsin, three products are detected on immunoblots
probed with S1CD, namely a 12 kDa product generated by
trypsin, and two additional bands at 8 and 6 kDa (Figure 5).
These bands are not present in the Raji parental cell line,
indicating that all three bands are attributable to the transfected
syndecan-1. As seen with the NMuMG cells, all three bands are
also phosphorylated on tyrosine (Figure 5).
Phosphorylated syndecan-1 core protein is cleaved to yield low-
molecular-mass products
The appearance of multiple phosphorylated C-terminal frag-
ments of the syndecan-1 core protein demonstrates that per-
vanadate treatment activates a cellular protease and a kinase that
recognize the core protein. This raises the question of whether or
not both enzymes act on the native transmembrane proteoglycan.
Upon treatment with heparitinase and chondroitin ABC lyase,
the native syndecan-1 proteoglycan can be resolved on SDS}
PAGE as a single core protein that migrates at 80 kDa (Figure
6A). After treatment of NMuMG cells with pervanadate, the
intact core protein is indeed phosphorylated on tyrosine (Figure
6B). As expected, trypsin treatment of the cells results in the loss
of both the 80 kDa phosphorylated band (Figure 6B) and the
corresponding immunostained syndecan-1 core protein (Figure
6A), with the concomitant appearance of the phosphorylated
12 kDa C-terminal fragment and smaller products.
The smaller products seen in pervanadate-treated cells are also
present in the absence of trypsin cleavage. When cells are treated
with pervanadate, S1CD-reactive bands appear at 6 and 8 kDa,
apparently produced by a cellular protease, with the additional
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Figure 6 Tyrosine phosphorylation of the syndecan-1 core protein
NMuMG cells were incubated with or without pervanadate for 15 min at 37 °C, then shifted to
4 °C. These incubations were also combined with either treatment with heparitinase and
chondroitin ABC lyase (Hep’ase) for 1 h at 37 °C or treatment with trypsin after the shift to 4 °C.
Detergent lysates of the cells were immunoprecipitated with S1CD, resolved by gel
electrophoresis, transferred to Zeta-probe membrane and immunostained with (A) S1CD or (B)
PY-20.
12 kDa band appearing after trypsin treatment (Figure 6A). In
cells treated with pervanadate the 6, 8 and 12 kDa products are
all phosphorylated on tyrosine (Figure 6B). These data suggest
that either the 6 and 8 kDa products are produced by a single
cleavage and run differently as a result of the addition of multiple
phosphates or more than one site is cleaved on syndecan-1 in
response to pervanadate treatment. As the size of the 6 and
8 kDa products is not affected by treatment of the cells with
trypsin, leading to yet smaller products, it is likely that the
endogenous cleavage occurs closer to the C-terminus than the
trypsin-recognition site.
Pervanadate treatment of NMuMG cells induces cleavage of most
of the cell surface syndecan-1
To determine the effectiveness of pervanadate in inducing cleav-
age of syndecan-1, the core protein and its cleavage products
were isolated from cells treated with pervanadate throughout a
30 min time course. The core protein is already diminished by
5 min of treatment and is greatly reduced by 30 min (Figure 7).
There is a corresponding increase in the C-terminal fragments.
At 5 min only the 6 kDa product can be detected and this
product continues to increase until 15 min. The 8 kDa product
can be detected by 15 min and continues to increase until 30 min.
The disappearance of the full-length core protein and sub-
sequent appearance of lower-molecular-mass products may re-
flect degradation of proteoglycan that has been rapidly internal-
ized, or it may represent a cell surface cleavage. These can be
distinguished by monitoring the appearance of syndecan-1 ecto-
domain in the culture medium, which is indicative of a cell-
surface-shedding mechanism. The addition of pervanadate for
30 min induces the release of syndecan-1 ectodomain into the
medium (Figure 8), shown by isolating total proteoglycan from
the medium and quantitatively analysing syndecan-1 on dot
blots with mAb 281±2, a mAb to the ectodomain of syndecan-1.
Untreated NMuMG cells shed only small amounts of syndecan-
1 ectodomain during a 30 min incubation (Figure 8).
Figure 7 Pervanadate treatment cleaves syndecan-1 core protein on the
cell surface and results in low-molecular-mass cleavage products
NMuMG cells treated with heparitinase and chondroitin ABC lyase (Hep’ase) were incubated
with pervanadate for 0, 5, 15 or 30 min at 37 °C. Alternatively, cells were treated with trypsin
without pervanadate incubation to generate the syndecan-1 C-terminal fragment. The cells were
lysed in detergent and syndecan-1 C-terminal fragments were immunoprecipitated with S1CD.
Immunoprecipitates were resolved by gel electrophoresis, transferred to Zeta-probe membrane
and immunostained with S1CD.
Figure 8 Syndecan-1 is shed into the medium of pervanadate-treated
NMuMG cells
NMuMG cells were incubated with or without pervanadate (no treatment) for 30 min at 37 °C.
Proteoglycan was isolated from the medium and cells on DEAE-Sephacel, then 3-fold dilutions
of the eluate were applied to Zeta-probe membranes and immunostained with mAb 281±2.
The C-terminal fragment produced in pervanadate retains the
hydrophobic membrane domain
The pervanadate-induced cleavage products migrate with much
lower apparent molecular masses than the trypsin-generated
fragment, indicating that they may be produced by intracellular
cleavage of the cytoplasmic domain. A major difference between
an intracellular and a cell surface cleavage would be retention of
the transmembrane domain, the latter cleavage site producing a
C-terminal fragment that retains hydrophobic properties. To test
for hydrophobicity, the fragments were subjected to Triton X-
114 phase separation in which hydrophobic membrane proteins
are isolated in the detergent phase. As a control, PLC-γ, a
cytoplasmic protein, was also isolated and partitioned. As
expected, PLC-γ is isolated in the aqueous phase, which is typical
of a non-membrane protein (Figure 9B). In contrast, both the
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Figure 9 C-Terminal fragment generated by pervanadate-induced cleavage
is hydrophobic
NMuMG cells treated with pervanadate or trypsin or untreated (none) were lysed in Triton X-
114. An aliquot of the sample prior to separation (®), or equal aliquots of either the aqueous
(Aq) or detergent (Det) phases after phase separation of the Triton X-114 were immuno-
precipitated with S1CD (A) or anti-PLC-γ (B) and then resolved by gel electrophoresis,
transferred to Zeta-probe membrane and immunostained with S1CD (A) or anti-PLC-γ (B).
Figure 10 Phosphorylation of syndecan-1 C-terminal fragment retards its
mobility in gel electrophoresis
S1CD immunoprecipitates from pervanadate-treated NMuMG cells were heated to 100 °C for
5 min and treated with or without potato acid phosphatase for 50 min at 32 °C. Immuno-
precipitates were resolved by gel electrophoresis, transferred to Zeta-probe membrane and
immunostained with (A) PY-20 or (B) S1CD. The C-terminal fragment derived by treatment of
the cells with trypsin is shown for comparison.
6 kDa fragment produced by pervanadate treatment and the
12 kDa product of trypsin treatment separate into the detergent
phase, indicating that they both retain at least part of the
transmembrane domain (Figure 9A). As both are detected by
S1CD, which recognizes the C-terminal 10 amino acids, this
demonstrates that both fragments contain the complete cyto-
plasmic domain as well as most or all of the transmembrane
domain.
Phosphorylation of syndecan-1 C-terminal fragment changes its
migration during gel electrophoresis
To determine if phosphorylation affects the migration of these
products, the isolated C-terminal fragments were treated with
potato acid phosphatase to eliminate the phosphorylation. As
seen previously, S1CD precipitates two proteins of molecular
mass 8 and 6 kDa from pervanadate-treated cells (Figure 10B)
that are phosphorylated (Figure 10A). Treatment with potato
acid phosphatase eliminates the tyrosine phosphorylation of
these proteins (Figure 10A). The dephosphorylated sample can
be detected with S1CD staining as a single 6 kDa band (Figure
10B). It thus appears that the 8 kDa product co-migrates with
the 6 kDa protein when it is dephosphorylated. As both proteins
are tyrosine phosphorylated, the 8 kDa band either contains
multiple tyrosine phosphorylations or is phosphorylated on
serine in addition to tyrosine. Similarly, the 14 kDa product seen
occasionally in pervanadate-treated cells after trypsinization is
most likely a more highly phosphorylated version of the 12 kDa
trypsin-cleavage product.
DISCUSSION
Syndecan-1 is phosphorylated on tyrosine in cells treated with
pervanadate, demonstrating that the syndecan-1 cytoplasmic
domain is a substrate for an intracellular kinase, presumably part
of an intracellular signal-transduction pathway. Syndecan-1 has
three conserved tyrosines in the cytoplasmic domain [1,27], one
of which (Y#)() lies in a consensus sequence for recognition by a
tyrosine kinase [25,26]. It is not known at present which, or if
more than one, of the tyrosines is phosphorylated. Concurrent
with the phosphorylation, although potentially as a separate
response to the activation of intracellular kinases, syndecan-1 is
cleaved into two components : the ectodomain is shed into the
medium and the cytoplasmic domain with all or part of the
transmembrane domain is retained with the cell. Although
phosphorylation of the cytoplasmic domain is detected prior to
shedding, it is not known whether it stimulates the shedding
process.
Kinases that rely on auto- or trans-phosphorylation for
activation are also inactivated by phosphatases that remove
these phosphates. Thus vanadate inhibition of phosphatases
would be predicted to release negative controls imposed on
cellular kinases and stimulate signal-transduction cascades in the
cell [29]. Indeed, orthovanadate and pervanadate have been used
previously in this manner to stimulate cellular responses that are
dependent upon phosphorylation cascades [29,37–41]. The effect
of pervanadate in the NMuMG cells may largely reflect this
function, together with enhanced retention of the phosphates
during treatment and protein isolation. The more rapid effect of
pervanadate compared with orthovanadate is probably due to its
greater efficacy as a phosphatase inhibitor, although the vana-
dates may also have differing specificities [40].
The identity of the kinase that phosphorylates syndecan-1 is
not known. It is postulated to be a tyrosine kinase that is
regulated by phosphorylation. As syndecan-1 is not readily
isolated in a phosphorylated form in the absence of pervanadate,
the kinase is not highly active in standard cell culture conditions.
An alternative is that the kinase is constitutively active and that
pervanadate blocks the rapid phosphate removal by an in-
tracellular phosphatase. This seems unlikely on the basis of
current knowledge of kinases in signal-transduction systems,
where kinase activity is believed to be transient. However, it
cannot be ruled out that the accumulation of phosphorylated
syndecan-1 over a period of hours during orthovanadate treat-
ment may reflect the accumulation of constitutively phosphoryl-
ated syndecan-1 which is normally subjected to rapid dephos-
phorylation by a vanadate-sensitive phosphatase.
Phosphorylation is an important regulator of cellular function
for other cell surface receptors that do not contain inherent
kinase activity, such as the integrins and the cadherins [42,43].
Members of the integrin family can be phosphorylated, and
binding of their ligands induces phosphorylation of intracellular
proteins including focal adhesion kinase [16] and paxillin [44].
Phosphorylation of catenins by transfection of cells with v-src
abolishes their interaction with cadherins and leads to changes in
cellular morphology [45]. Similarly, phosphorylation of syn-
decan-1 may alter its interaction with other cellular proteins. The
phosphotyrosine may provide a binding site for the SH2 domains
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of regulatory proteins, thus participating in the assembly of an
adhesive signalling complex, or may alter its anchorage to the
cytoskeleton. Clustering of syndecan-1 using antibodies, thus
mimicking its aggregation into adhesive sites, enhances its
retention in the Triton-insoluble cytoskeletal residue and causes
it to align with actin filaments [11,12]. This alignment is dependent
on the presence of the cytoplasmic domain [11].
In addition to stimulating phosphorylation of syndecan-1,
pervanadate treatment induces cleavage of the proteoglycan and
the release of its ectodomain into the culture medium. This
release of syndecan-1 allows rapid changes in cell surface
expression and may be a means of changing the cellular response
to heparan sulphate-binding ligands such as fibroblast growth
factors or extracellular matrix ligands. Extracellular proteolytic
cleavage of proteins is a common mechanism of altering cell
surface expression of a wide variety of molecules and is typically
stimulated by treatment with phorbol esters [e.g. phorbol 12-
myristate 13-acetate (PMA)], as shown for L-selectin [46], tumour
necrosis factor α receptor [47,48], amyloid precursor protein
[49,50], colony-stimulating factor-1 (CSF-1) [51] and CSF-1
receptor [52].
PMA, an activator of the serine}threonine protein kinase C
(PKC), has been shown to stimulate release of proteoglycans
from the cell surface concurrent with changes in cellular mor-
phology and cell proliferation [53]. Similarly, we find that the
shedding of syndecan-1 is promoted by PMA and that the PMA-
induced shedding is reduced by treatment with staurosporine,
an inhibitor of PKC (J. Reiland, V. L. Ott, C. S. Lebakken, C.
Yeaman, J. McCarthy and A. C. Rapraeger, unpublished work).
Treatment of NMuMG cells with 200 nM PMA generates the
6 kDa C-terminal cleavage fragment, although no tyrosine phos-
phorylation is detected (V. L. Ott and A. C. Rapraeger, un-
published work). This suggests that one mechanism by which
pervanadate may induce shedding is by activation of PKC. This
is unlikely to be a direct effect as PKC activity is not known to
be controlled by phosphorylation. Also, as PKC is a serine}
threonine kinase, it cannot be directly responsible for the tyrosine
phosphorylation of syndecan-1. Furthermore, as we fail to detect
syndecan-1 tyrosine phosphorylation in response to PMA treat-
ment, the kinase that phosphorylates syndecan-1 does not appear
to be downstream from PKC. It is a possibility, however, that
activation of a kinase upstream from PKC leads to both PKC
activation and syndecan-1 phosphorylation on tyrosine. Shed-
ding of syndecan-1 also occurs in response to other stimuli,
suggesting that they also may act through PKC. It is rapidly shed
from the cell surface when cells are treated with EDTA to
promote detachment from their substratum [54]. Transformed
mouse keratinocytes expressing high levels of Ha-ras p21 display
increased shedding of syndecan-1 [55]. Also, NIH-3T3 cells
release syndecan-1 into the medium when treated with both
transforming growth factor β and basic fibroblast growth factor
[56].
The current data do not demonstrate that syndecan-1 phos-
phorylation is a prerequisite for the shedding process to occur,
although they do occur in the same time frame. It is perhaps
more likely that the shedding occurs as a separate pathway that
activates a membrane protease. The tumour necrosis factor α
receptor and B-amyloid precursor protein, examples of proteins
that are phosphorylated and cleaved in response to PMA
treatment, are cleaved even when phosphorylation is blocked by
mutation of the cytoplasmic tyrosines and serines [57,58]. Mu-
tation of the serines and tyrosines in the syndecan-1 cytoplasmic
domain will be required to address whether phosphorylation of
syndecan-1 itself is required for shedding.
The intracellular kinases that are activated by pervanadate
and lead to phosphorylation and cleavage of syndecan-1 are not
known at present. Their activation may occur through signalling
of either growth factors or adhesive events ; changes in the latter
are known to affect syndecan-1 cleavage [54]. This is likely to
provide a mechanism whereby the participation of the heparan
sulphate proteoglycan in cell attachment, migration and response
to heparan sulphate-binding growth factors is regulated.
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